EMBARGOED FOR RELEASE: 3 P.M. (CT), MONDAY, MAY 21, 2012
Media Advisory: To contact author Avital Harari, M.D., call Rachel Champeau at 310-794-0777 or email firstname.lastname@example.org. To contact invited critique author Quan-Yang Duh, M.D., call Elizabeth Fernandez at 415-514-1592 or email email@example.com.
CHICAGO– A review of medical records of patients treated at an academic tertiary care center suggests that obese patients present to their physicians with more advanced stage and more aggressive forms of papillary thyroid cancer (PTC), according to a report published Online First by Archives of Surgery, a JAMA Network publication.
Thyroid cancer is on the rise on theUnited Statesand most of the increase is due to PTC, although the authors write that it is debatable whether the increase is caused by an enhanced risk of cancer or an increase in detection. Obesity is recognized as a risk factor for a variety of cancers, the authors provide as study background.
“Our study shows that those patients with increasing BMI have a progressively increasing risk in presenting with late-stage PTC. This finding is especially seen in the obese and morbidly obese populations,” the researchers comment.
Avital Harari, M.D., and colleagues at the UCLA David Geffen School of Medicine,Los Angeles, reviewed the medical records of all patients older than 18 who underwent total thyroidectomy (removal of most or all of the thyroid gland) as an initial procedure for PTC or its variants from January 2004 through March 2011.
The final analysis included 443 patients with an average age of 48.2 years. Patients were divided into four BMI (body mass index) groups: normal (18.5-24.9), overweight (25-29.9), obese (30-39.9) and morbidly obese (≥40).
“Greater BMI was associated with more advanced disease stage at presentation. Specifically, the obese and morbidly obese categories presented more as stage III or IV disease,” according to the study results.
Researchers also note the obese and morbidly obese groups also presented with a higher prevalence of PTC tall cell variant, “suggesting that these groups have a higher risk of more aggressive tumor types.”
“Given our findings, we believe that obese patients are at a higher risk of developing aggressive thyroid cancers and thus should be screened for thyroid cancer by sonography, which has been shown to be more sensitive in detecting thyroid cancer than physical examination alone,” the authors conclude.
(Arch Surg. Published Online May 21, 2012. doi:10.1001/archsurg.2012.713. Available pre-embargo to the media at media.jamanetwork.com.)
Editor’s Note: The statistical support was funded through an intramural faculty startup grant. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
Invited Critique: Thyroid Cancer Operations for Obese Patients
In an invited critique, Quan-Yang Duh, M.D., of theUniversityofCalifornia,San Francisco, writes: “Harari and colleagues from UCLA (UniversityofCalifornia,Los Angeles) showed us one more reason to be concerned about the current obesity epidemic – obese patients have more advanced thyroid cancer.”
Duh continues: “This parallel increase in the rates of obesity and thyroid cancer is intriguing, but without a much larger population study, we cannot determine whether obesity causes thyroid cancer. However, the authors found that higher body mass index is associated with a later stage of thyroid cancer.”
“For obese patients with papillary thyroid cancer, the bad news is that the cancer is likely to be more advanced. The good news is that thyroid operation remains safe even in obese patients with advanced disease,” Duh concludes.
(Arch Surg. Published online May 21, 2012. doi:10.1001/archsurg.2012.911. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email firstname.lastname@example.org.